COMPAZINE
LOE ApproachingNDARECTALSUPPOSITORY
Approved
Jan 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is a first-generation antipsychotic and antiemetic small molecule approved in 1959, available as a rectal suppository formulation. The drug works via dopamine antagonism in the chemoreceptor trigger zone and vomiting center. It is used primarily for nausea, vomiting, and psychiatric indications across various patient populations.
LOE Approaching
Competitive pressure is moderate (30/100), signaling a mature market with limited growth opportunity and likely smaller commercial teams focused on retention and efficiency.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career growth potential, as the product is in late-stage lifecycle with minimal commercial expansion. Career value lies in cost management, market access strategy, and defending market share in a mature therapeutic area.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.